M
Michael Doumas
Researcher at Aristotle University of Thessaloniki
Publications - 381
Citations - 7476
Michael Doumas is an academic researcher from Aristotle University of Thessaloniki. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 39, co-authored 298 publications receiving 5836 citations. Previous affiliations of Michael Doumas include University of Ioannina & Georgetown University.
Papers
More filters
Journal ArticleDOI
Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study
Stella Douma,Konstantinos Petidis,Michael Doumas,Panagiota Papaefthimiou,Areti Triantafyllou,Niki Kartali,Nikolaos Papadopoulos,K. Vogiatzis,Chrysanthos Zamboulis +8 more
TL;DR: The prevalence of primary hyperaldosteronism in patients with resistant hypertension was high, and it was substantially lower than previously reported, suggesting that the notion of an epidemic of primaryhyperaldoster onism in the general unselected hypertensive population is not supported.
Journal ArticleDOI
A novel C5a receptor-tissue factor cross-talk in neutrophils links innate immunity to coagulation pathways.
Konstantinos Ritis,Michael Doumas,Dimitrios C. Mastellos,Anastasia Micheli,Stavros Giaglis,Paola Magotti,Stavros Rafail,Georgios Kartalis,Paschalis Sideras,John D. Lambris +9 more
TL;DR: It is demonstrated that antiphospholipid Ab-induced complement activation and downstream signaling via C5a receptors in neutrophils leads to the induction of tissue factor (TF), a key initiating component of the blood coagulation cascade.
Journal ArticleDOI
Exercise Capacity and Mortality in Older Men A 20-Year Follow-Up Study
Peter Kokkinos,Jonathan Myers,Charles Faselis,Demosthenes B. Panagiotakos,Michael Doumas,Andreas Pittaras,Athanasios J. Manolis,John Peter Kokkinos,Pamela Karasik,Michael Greenberg,Vasilios Papademetriou,Ross D. Fletcher +11 more
TL;DR: Exercise capacity is an independent predictor of all-cause mortality in older men, with most survival benefits achieved in those with an exercise capacity >5 METs, and survival improved significantly when unfit individuals became fit.
Journal ArticleDOI
Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial.
Evdoxia Kyriazopoulou,Garyfallia Poulakou,Haralampos J. Milionis,Simeon Metallidis,Georgios Adamis,Konstantinos Tsiakos,Archontoula Fragkou,Aggeliki Rapti,Christina Damoulari,Massimo Fantoni,Ioannis Kalomenidis,Georgios Chrysos,Andrea Angheben,Ilias Kainis,Zoi Alexiou,Francesco Castelli,Francesco Saverio Serino,Maria Tsilika,Petros Bakakos,Emanuele Nicastri,Vassiliki Tzavara,Evangelos Kostis,Lorenzo Dagna,Panagiotis Koufargyris,Katerina Dimakou,Spyridon Savvanis,Glykeria Tzatzagou,Maria Giovanna Chini,Giulio Cavalli,Matteo Bassetti,Konstantina Katrini,Vasileios Kotsis,George Tsoukalas,Carlo Selmi,Ioannis Bliziotis,Michael Samarkos,Michael Doumas,Sofia Ktena,Aikaterini Masgala,Ilias Papanikolaou,Maria Kosmidou,Dimitra Melia Myrodia,Aikaterini Argyraki,Chiara Simona Cardellino,Katerina Koliakou,Eleni Ioanna Katsigianni,Vassiliki Rapti,Efthymia Giannitsioti,Antonella Cingolani,Styliani Micha,Karolina Akinosoglou,Orestis Liatsis-Douvitsas,Styliani Symbardi,Nikolaos K. Gatselis,Maria Mouktaroudi,Giuseppe Ippolito,Eleni Florou,Antigone Kotsaki,Mihai G. Netea,Mihai G. Netea,Jesper Eugen-Olsen,Miltiades Kyprianou,Periklis Panagopoulos,George N. Dalekos,Evangelos J. Giamarellos-Bourboulis +64 more
TL;DR: The SAVE-MORE trial as discussed by the authors evaluated the efficacy and safety of anakinra, an IL-1α/β inhibitor, in 594 patients with COVID-19 at risk of progressing to respiratory failure.
Journal ArticleDOI
Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment: The Action to Control Cardiovascular Risk in Diabetes Study
Vasilios Papademetriou,Laura C. Lovato,Costas Tsioufis,William C. Cushman,William B. Applegate,Amy Mottle,Zubin Punthakee,Eric S. Nylen,Michael Doumas +8 more
TL;DR: For patients with type 2 diabetes at high CV risk but no CKD, fenofibrate therapy added to statin reduced the CV mortality and the rate of fatal and non-fatal CHF.